AVNT / USDC

AVNT / TRY

AVNT / USDT

USUAL / USDC

USUAL / USDT

USUAL / TRY

MANTA / TRY

MANTA / USDC

MANTA / BTC

SKL / BTC

TURTLE / BNB

TURTLE / USDT

TURTLE / USDC

PARTI / USDC

TURTLE / TRY

PARTI / USDT

PARTI / TRY

TURTLE / FDUSD

PARTI / FDUSD

PARTI / BNB

S J LOGISTICS (INDIA) LTD

PRECISION WIRES INDIA LTD

INDO TECH TRANSFORM LTD.

FINBUD FINANCIAL SERV LTD

VINDHYA TELELINKS LTD

SAFE ENTER RETAIL FIX LTD

SALZER ELECTRONICS LTD

TVS ELECTRONICS LTD

NECTAR LIFESCIENCES LTD.

GRETEX CORPORATE SERVICES

S A TECH SOFTWARE INDIA L

PRESSTONIC ENGINEERING L

VDEAL SYSTEM LIMITED

FISCHER MEDICAL VENTURE L

HARIOM PIPE INDUSTRIES L

TEAMO PRODUCTIONS HQ LTD

SAHASRA ELECTRONIC SOLU L

ENFUSE SOLUTIONS LIMITED

DYNEMIC PRODUCTS LIMITED

DREDGING CORP OF INDIA

Click here to get full coverage on Determination of key functional structures of an amorphous VHL-based SMARCA2 PROTAC - Nature

Determination of key functional structures of an amorphous VHL-based SMARCA2 PROTAC  Nature

Determination of key functional structures of an amorphous VHL-based SMARCA2 PROTAC - Nature

Click here to get full coverage on ASCO 2025: Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitor Belzutifan in Von Hippel-Lindau (VHL) Disease–associated Neoplasms: 5-Year Follow-up of the Phase 2 LITESPARK-004 Study - UroToday

ASCO 2025: Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitor Belzutifan in Von Hippel-Lindau (VHL) Disease–associated Neoplasms: 5-Year Follow-up of the Phase 2 LITESPARK-004 Study  UroToday

ASCO 2025: Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitor Belzutifan in Von Hippel-Lindau (VHL) Disease–associated Neoplasms: 5-Year Follow-up of the Phase 2 LITESPARK-004 Study - UroToday

Click here to get full coverage on Belzutifan Displays Robust Activity in VHL-Associated RCC - OncLive

Belzutifan Displays Robust Activity in VHL-Associated RCC  OncLive

Belzutifan Displays Robust Activity in VHL-Associated RCC - OncLive

Click here to get full coverage on Maryam Soleimani’s Highlights from VIRO 2025 on VHL and Kidney Cancer - Oncodaily

Maryam Soleimani’s Highlights from VIRO 2025 on VHL and Kidney Cancer  Oncodaily

Maryam Soleimani’s Highlights from VIRO 2025 on VHL and Kidney Cancer - Oncodaily

Click here to get full coverage on Case Report: von Hippel-Lindau (VHL) disease: a young female presenting with multiple organ tumors - Frontiers

Case Report: von Hippel-Lindau (VHL) disease: a young female presenting with multiple organ tumors  Frontiers

Case Report: von Hippel-Lindau (VHL) disease: a young female presenting with multiple organ tumors - Frontiers

Click here to get full coverage on Pseudohypoxia caused by germline genetic alterations in the VHL gene is associated with increased diabetes and cardiovascular risk: a UK biobank study - BioMed Central

Pseudohypoxia caused by germline genetic alterations in the VHL gene is associated with increased diabetes and cardiovascular risk: a UK biobank study  BioMed Central

Pseudohypoxia caused by germline genetic alterations in the VHL gene is associated with increased diabetes and cardiovascular risk: a UK biobank study - BioMed Central

Click here to get full coverage on What my sister’s life and death taught me about the NIH - statnews.com

What my sister’s life and death taught me about the NIH  statnews.com

What my sister’s life and death taught me about the NIH - statnews.com

Click here to get full coverage on HIFα isoform specific activities drive cell-type specificity of VHL -associated oncogenesis - Nature

HIFα isoform specific activities drive cell-type specificity of VHL -associated oncogenesis  Nature

HIFα isoform specific activities drive cell-type specificity of VHL -associated oncogenesis - Nature

Click here to get full coverage on Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 5 - ACS Publications

Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 5  ACS Publications

Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 5 - ACS Publications

Click here to get full coverage on The Way Forward for the Virtual Health Library After 27 Years - Pan American Health Organization (PAHO)

The Way Forward for the Virtual Health Library After 27 Years  Pan American Health Organization (PAHO)

The Way Forward for the Virtual Health Library After 27 Years - Pan American Health Organization (PAHO)

Click here to get full coverage on France’s HAS Grants Post-MA Early Access for MSD’s Welireg in VHL-Associated Localized Tumors - NAVLIN DAILY

France’s HAS Grants Post-MA Early Access for MSD’s Welireg in VHL-Associated Localized Tumors  NAVLIN DAILY

France’s HAS Grants Post-MA Early Access for MSD’s Welireg in VHL-Associated Localized Tumors - NAVLIN DAILY

Click here to get full coverage on European Commission Approves Belzutifan for VHL Disease–Associated Tumors, Advanced ccRCC - OncLive

European Commission Approves Belzutifan for VHL Disease–Associated Tumors, Advanced ccRCC  OncLive

European Commission Approves Belzutifan for VHL Disease–Associated Tumors, Advanced ccRCC - OncLive

Click here to get full coverage on Belzutifan Demonstrates Durable Activity in VHL Disease Tumors - Vivek Narayan - UroToday

Belzutifan Demonstrates Durable Activity in VHL Disease Tumors - Vivek Narayan  UroToday

Belzutifan Demonstrates Durable Activity in VHL Disease Tumors - Vivek Narayan - UroToday

Click here to get full coverage on A small-molecule VHL molecular glue degrader for cysteine dioxygenase 1 - Nature

A small-molecule VHL molecular glue degrader for cysteine dioxygenase 1  Nature

A small-molecule VHL molecular glue degrader for cysteine dioxygenase 1 - Nature

Click here to get full coverage on Timing of Real-World Belzutifan-Related AEs Varies Between VHL-Associated Tumors and Sporadic RCC - OncLive

Timing of Real-World Belzutifan-Related AEs Varies Between VHL-Associated Tumors and Sporadic RCC  OncLive

Timing of Real-World Belzutifan-Related AEs Varies Between VHL-Associated Tumors and Sporadic RCC - OncLive

Click here to get full coverage on Drugit: crowd-sourcing molecular design of non-peptidic VHL binders - Nature

Drugit: crowd-sourcing molecular design of non-peptidic VHL binders  Nature

Drugit: crowd-sourcing molecular design of non-peptidic VHL binders - Nature

Click here to get full coverage on In-cell proximity target validation methods for heterobifunctional molecules with CRBN- or VHL-binder using AirID - Nature

In-cell proximity target validation methods for heterobifunctional molecules with CRBN- or VHL-binder using AirID  Nature

In-cell proximity target validation methods for heterobifunctional molecules with CRBN- or VHL-binder using AirID - Nature

Click here to get full coverage on Molecular dynamics reveal potential effects of novel VHL variants on VHL-Elongin C binding in ccRCC patients from Eastern India - Nature

Molecular dynamics reveal potential effects of novel VHL variants on VHL-Elongin C binding in ccRCC patients from Eastern India  Nature

Molecular dynamics reveal potential effects of novel VHL variants on VHL-Elongin C binding in ccRCC patients from Eastern India - Nature

Click here to get full coverage on Stick it with VHL - Nature

Stick it with VHL - Nature

Click here to get full coverage on CRISPR-Cas9 genetic screens reveal regulation of TMPRSS2 by the Elongin BC-VHL complex - Nature

CRISPR-Cas9 genetic screens reveal regulation of TMPRSS2 by the Elongin BC-VHL complex  Nature

CRISPR-Cas9 genetic screens reveal regulation of TMPRSS2 by the Elongin BC-VHL complex - Nature

Click here to get full coverage on VHL ameliorates arecoline-induced oral submucosal fibrosis by promoting HDAC6 ubiquitination and blocking NF-κB pathway - Nature

VHL ameliorates arecoline-induced oral submucosal fibrosis by promoting HDAC6 ubiquitination and blocking NF-κB pathway  Nature

VHL ameliorates arecoline-induced oral submucosal fibrosis by promoting HDAC6 ubiquitination and blocking NF-κB pathway - Nature

Click here to get full coverage on VHL & LILACS - Launch of the 2025 Calendar of Meetings with the MedCarib Network - Pan American Health Organization (PAHO)

VHL & LILACS - Launch of the 2025 Calendar of Meetings with the MedCarib Network  Pan American Health Organization (PAHO)

VHL & LILACS - Launch of the 2025 Calendar of Meetings with the MedCarib Network - Pan American Health Organization (PAHO)

Click here to get full coverage on Belzutifan Approved to Treat Tumors Linked to Inherited Disorder VHL - National Cancer Institute (.gov)

Belzutifan Approved to Treat Tumors Linked to Inherited Disorder VHL  National Cancer Institute (.gov)

Belzutifan Approved to Treat Tumors Linked to Inherited Disorder VHL - National Cancer Institute (.gov)

Click here to get full coverage on Europe Approves Its First Drug for Von Hippel-Lindau Tumors - Medscape

Europe Approves Its First Drug for Von Hippel-Lindau Tumors  Medscape

Europe Approves Its First Drug for Von Hippel-Lindau Tumors - Medscape

Click here to get full coverage on Mother diagnosed with terminal illness finds hope in clinical trial funded by supporters worldwide - WGAL

Mother diagnosed with terminal illness finds hope in clinical trial funded by supporters worldwide  WGAL

Mother diagnosed with terminal illness finds hope in clinical trial funded by supporters worldwide - WGAL

Click here to get full coverage on VHL Care Center - Roswell Park Comprehensive Cancer Center

VHL Care Center  Roswell Park Comprehensive Cancer Center

VHL Care Center - Roswell Park Comprehensive Cancer Center

Click here to get full coverage on Saturation genome editing maps the functional spectrum of pathogenic VHL alleles - Nature

Saturation genome editing maps the functional spectrum of pathogenic VHL alleles  Nature

Saturation genome editing maps the functional spectrum of pathogenic VHL alleles - Nature

Click here to get full coverage on Go inside the one-of-a-kind Visible Heart Lab - Medtronic

Go inside the one-of-a-kind Visible Heart Lab  Medtronic

Go inside the one-of-a-kind Visible Heart Lab - Medtronic

Click here to get full coverage on VHL mosaicism: the added value of multi-tissue analysis - Nature

VHL mosaicism: the added value of multi-tissue analysis  Nature

VHL mosaicism: the added value of multi-tissue analysis - Nature

Click here to get full coverage on Laparoscopic Partial Nephrectomy for Multiple Complex Renal Masses in a Patient With Von Hippel-Lindau Syndrome: A Case Report - Cureus

Laparoscopic Partial Nephrectomy for Multiple Complex Renal Masses in a Patient With Von Hippel-Lindau Syndrome: A Case Report  Cureus

Laparoscopic Partial Nephrectomy for Multiple Complex Renal Masses in a Patient With Von Hippel-Lindau Syndrome: A Case Report - Cureus

Click here to get full coverage on Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma - Nature

Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma  Nature

Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma - Nature

Click here to get full coverage on Effects of Germline VHL Deficiency on Growth, Metabolism, and Mitochondria - The New England Journal of Medicine

Effects of Germline VHL Deficiency on Growth, Metabolism, and Mitochondria  The New England Journal of Medicine

Effects of Germline VHL Deficiency on Growth, Metabolism, and Mitochondria - The New England Journal of Medicine

Click here to get full coverage on Critical role of VHL/BICD2/STAT1 axis in crystal-associated kidney disease - Nature

Critical role of VHL/BICD2/STAT1 axis in crystal-associated kidney disease  Nature

Critical role of VHL/BICD2/STAT1 axis in crystal-associated kidney disease - Nature

Click here to get full coverage on VHL suppresses UBE3B-mediated breast tumor growth and metastasis | Cell Death & Disease - Nature

VHL suppresses UBE3B-mediated breast tumor growth and metastasis | Cell Death & Disease  Nature

VHL suppresses UBE3B-mediated breast tumor growth and metastasis | Cell Death & Disease - Nature

Click here to get full coverage on Loss of PBRM1 rescues VHL dependent replication stress to promote renal carcinogenesis - Nature

Loss of PBRM1 rescues VHL dependent replication stress to promote renal carcinogenesis  Nature

Loss of PBRM1 rescues VHL dependent replication stress to promote renal carcinogenesis - Nature

Click here to get full coverage on A ‘game-changer’ for von Hippel-Lindau disease treatment - MD Anderson Cancer Center

A ‘game-changer’ for von Hippel-Lindau disease treatment  MD Anderson Cancer Center

A ‘game-changer’ for von Hippel-Lindau disease treatment - MD Anderson Cancer Center

Click here to get full coverage on VHL, the story of a tumour suppressor gene - Nature

VHL, the story of a tumour suppressor gene  Nature

VHL, the story of a tumour suppressor gene - Nature

Click here to get full coverage on CRISPR-Mediated VHL Knockout Generates an Improved Model for Metastatic Renal Cell Carcinoma - Nature

CRISPR-Mediated VHL Knockout Generates an Improved Model for Metastatic Renal Cell Carcinoma  Nature

CRISPR-Mediated VHL Knockout Generates an Improved Model for Metastatic Renal Cell Carcinoma - Nature

Click here to get full coverage on Tumors in von Hippel–Lindau Syndrome: From Head to Toe—Comprehensive State-of-the-Art ReviewRadioGraphics - RSNA Journals

Tumors in von Hippel–Lindau Syndrome: From Head to Toe—Comprehensive State-of-the-Art ReviewRadioGraphics  RSNA Journals

Tumors in von Hippel–Lindau Syndrome: From Head to Toe—Comprehensive State-of-the-Art ReviewRadioGraphics - RSNA Journals

Click here to get full coverage on VHL suppresses RAPTOR and inhibits mTORC1 signaling in clear cell renal cell carcinoma - Nature

VHL suppresses RAPTOR and inhibits mTORC1 signaling in clear cell renal cell carcinoma  Nature

VHL suppresses RAPTOR and inhibits mTORC1 signaling in clear cell renal cell carcinoma - Nature

Click here to get full coverage on Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease - The New England Journal of Medicine

Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease  The New England Journal of Medicine

Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease - The New England Journal of Medicine

Click here to get full coverage on A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo - Nature

A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo  Nature

A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo - Nature

Click here to get full coverage on Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC | Communications Biology - Nature

Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC | Communications Biology  Nature

Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC | Communications Biology - Nature

Click here to get full coverage on Prevalence, birth incidence, and penetrance of von Hippel–Lindau disease (vHL) in Denmark - Nature

Prevalence, birth incidence, and penetrance of von Hippel–Lindau disease (vHL) in Denmark  Nature

Prevalence, birth incidence, and penetrance of von Hippel–Lindau disease (vHL) in Denmark - Nature

Click here to get full coverage on VHL: A very hip ligase - PNAS

VHL: A very hip ligase - PNAS

Click here to get full coverage on Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation - Nature

Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation  Nature

Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation - Nature

Click here to get full coverage on Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACs | Communications Medicine - Nature

Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACs | Communications Medicine  Nature

Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACs | Communications Medicine - Nature

Click here to get full coverage on FBXO22 promotes glioblastoma malignant progression by mediating VHL ubiquitination and degradation - Nature

FBXO22 promotes glioblastoma malignant progression by mediating VHL ubiquitination and degradation  Nature

FBXO22 promotes glioblastoma malignant progression by mediating VHL ubiquitination and degradation - Nature

Click here to get full coverage on Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules - Nature

Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules  Nature

Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules - Nature

Click here to get full coverage on NMPA Approves Belzutifan for VHL in RCC, CNS Hemangioblastomas, or pNETs - OncLive

NMPA Approves Belzutifan for VHL in RCC, CNS Hemangioblastomas, or pNETs  OncLive

NMPA Approves Belzutifan for VHL in RCC, CNS Hemangioblastomas, or pNETs - OncLive

Click here to get full coverage on Changing the Life of a Patient with von Hippel-Lindau Syndrome - National Cancer Institute (.gov)

Changing the Life of a Patient with von Hippel-Lindau Syndrome  National Cancer Institute (.gov)

Changing the Life of a Patient with von Hippel-Lindau Syndrome - National Cancer Institute (.gov)

Click here to get full coverage on The Long Road to Understanding Kidney Cancer - National Institutes of Health (.gov)

The Long Road to Understanding Kidney Cancer  National Institutes of Health (.gov)

The Long Road to Understanding Kidney Cancer - National Institutes of Health (.gov)

Click here to get full coverage on VHL inactivation without hypoxia is sufficient to achieve genome hypermethylation - Nature

VHL inactivation without hypoxia is sufficient to achieve genome hypermethylation  Nature

VHL inactivation without hypoxia is sufficient to achieve genome hypermethylation - Nature

Click here to get full coverage on VHL: Cullin-g the Hypoxic Response - ScienceDirect.com

VHL: Cullin-g the Hypoxic Response  ScienceDirect.com

VHL: Cullin-g the Hypoxic Response - ScienceDirect.com

Click here to get full coverage on CUL2-mediated clearance of misfolded TDP-43 is paradoxically affected by VHL in oligodendrocytes in ALS - Nature

CUL2-mediated clearance of misfolded TDP-43 is paradoxically affected by VHL in oligodendrocytes in ALS  Nature

VHL

Price Chart

Key Statistics

Technicals

About VHL

Latest News

Determination of key functional structures of an amorphous VHL-based SMARCA2 PROTAC - Nature

ASCO 2025: Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitor Belzutifan in Von Hippel-Lindau (VHL) Disease–associated Neoplasms: 5-Year Follow-up of the Phase 2 LITESPARK-004 Study - UroToday

Belzutifan Displays Robust Activity in VHL-Associated RCC - OncLive

Advanced Charts

Top Gainers

Top Losers